Renub Research has recently published a report titled “Japan In-Vitro Diagnostics (IVD) Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis” providing a detailed industry analysis that includes market share insights. In addition, the report covers research on competitors and regions and current advancements in the Japan In-Vitro Diagnostics (IVD) Market. The Japan In-Vitro Diagnostics (IVD) Industry shall experience a CAGR of nearly 3.53% from 2022 to 2028. The Japan In-Vitro Diagnostics (IVD) market is undergoing an increasing demand for molecular diagnostic tests due to the rise in chronic diseases and the need for personalized medicine. There is also a shift towards automation and digitalization, which can lead to faster and more accurate testing.
Additionally, there is a growing focus on preventive healthcare and early detection, leading to the development of new screening tests. Finally, the regulatory environment in Japan is evolving, with changes in the approval process for IVD products, aiming to streamline the process and encourage innovation and competition. For instance, The Pharmaceuticals and Medical Devices Agency (PMDA) has implemented new guidelines for IVD products to simplify the approval process and reduce the time and cost of bringing new products to the Japan In-Vitro Diagnostics (IVD) market.
Japan is one of the quickest aging populations globally, with approximately 28% of its population aged 65 or older. This demographic shift has led to increased chronic diseases like cancer, diabetes, and cardiovascular disease, which require regular monitoring and testing, resulting in a growing demand for IVD tests and devices to aid in the early detection, diagnosis, and management of these diseases. Furthermore, Japan’s highly developed healthcare system is home to some of the world’s leading medical technology companies. As a result, the country has been at the forefront of developing advanced IVD tests and devices widely used in healthcare settings.
The Japanese government has also implemented several policies to support the growth of the IVD market, including promoting the development of innovative technologies, increasing reimbursement rates for IVD tests and devices, and encouraging the use of personalized medicine.
Genetic Testing has Sovereignty in Japan’s In Vitro Diagnostics (IVD) Market
As the population ages, they become more susceptible to genetic variations that can increase their risk of developing certain diseases. Therefore, in vitro diagnostics (IVD) tests that detect genetic variations, also known as molecular diagnostics tests, are becoming increasingly crucial for the aging population. In addition, these tests can help in the early detection, diagnosis, and management of chronic diseases, such as cancer and cardiovascular disease, which are more prevalent among older adults.
Genetic IVD tests can also be crucial in personalized medicine, as they can help healthcare providers develop tailored treatment plans based on a patient’s genetic makeup. For example, a genetic test can help determine if a patient is at higher risk for developing certain types of cancer. Therefore, the patient can receive more personalized and targeted cancer screening and prevention measures.
Japan has a growing demand for non-invasive prenatal testing (NIPT). NIPT is a type of genetic testing that can detect chromosomal abnormalities in a developing fetus without invasive procedures such as amniocentesis, leading to an increase in the adoption of NIPT in Japan, which is driving growth in the genetic testing in Japan in vitro diagnostic (IVD) market.
Japan’s advanced healthcare system, regulatory environment, and the presence of leading medical technology companies have contributed to the dominance of the genetic testing segment in the country’s IVD market. In addition, the PMDA’s new guidelines have also encouraged innovation and competition, further fueling the rise of genetic testing in the market.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=japan-in-vitro-diagnostics-market-p.php
Some major players operating in Japan’s in vitro diagnostic (IVD) market include Roche Diagnostics, Abbott Laboratories, Biomerieux, Danaher Corporation, Becton, Bio-Rad Laboratories, Inc., Sysmex Corporation, and Thermo Fisher Scientific Inc.
Competition in the Japanese in vitro diagnostic (IVD) market arises from various factors, such as the rising demand for IVD tests and devices due to the elderly population and the rise in the cases of chronic diseases, the presence of leading medical technology companies in Japan competing to develop and market advanced IVD tests and devices, the evolving regulatory environment that encourages innovation and competition, and the growing emphasis on preventive healthcare and early detection leading to the development of new screening tests.
Segments – By segments, the Japan’s in vitro diagnostic (IVD) Market is broken up into 8 viewpoints
- United States
- United Kingdom
- Saudi Arabia
Key Players – All the major players in Japan’s in vitro diagnostic (IVD) Market have been covered from 3 Viewpoints (Overview, Recent Developments, and Sales Analysis)
- Roche Diagnostics
- Abbott Laboratories
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: [email protected]